Literature DB >> 8781441

High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox.

C Ding1, A Kume, H Björgvinsdóttir, R G Hawley, N Pech, M C Dinauer.   

Abstract

The X-linked form of chronic granulomatous disease (X-CGD) results from mutations in the gene encoding gp91phox, a 91-kD membrane glycoprotein that is the larger subunit of the respiratory burst oxidase cytochrome b. In this study, a new retroviral vector for expression of human gp91phox, MSCV-h91Neo, based on murine stem cell virus vectors, was evaluated using a human X-CGD myeloid cell line (X-CGD PLB-985 cells) and murine bone marrow cells. Expression of recombinant gp91phox in transduced X-CGD PLB-985 cells was substantially improved compared with levels achieved previously using a different retroviral construct, and respiratory burst oxidase activity was fully reconstituted in the majority of clones analyzed. Expression of gp91phox transcripts was also observed in primary and secondary murine colony-forming unit-spleen derived from transduced bone marrow cells. Furthermore, respiratory burst activity was restored to granulocyte-monocyte progeny of transduced X-CGD mice bone marrow cells cultured in vitro. This observation is the first reported use of gene transfer to correct the enzymatic defect in murine CGD phagocytes and is also consistent with the high conservation of the oxidase complex among different species. Taken together, these data suggest that the MSCV-h91Neo vector may be useful for gene replacement therapy in X-linked CGD, in which high-level reconstitution of phagocyte oxidase activity may be important for full correction of phagocyte microbicidal function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.

Authors:  Jacinta Bustamante; Andres A Arias; Guillaume Vogt; Capucine Picard; Lizbeth Blancas Galicia; Carolina Prando; Audrey V Grant; Christophe C Marchal; Marjorie Hubeau; Ariane Chapgier; Ludovic de Beaucoudrey; Anne Puel; Jacqueline Feinberg; Ethan Valinetz; Lucile Jannière; Céline Besse; Anne Boland; Jean-Marie Brisseau; Stéphane Blanche; Olivier Lortholary; Claire Fieschi; Jean-François Emile; Stéphanie Boisson-Dupuis; Saleh Al-Muhsen; Bruce Woda; Peter E Newburger; Antonio Condino-Neto; Mary C Dinauer; Laurent Abel; Jean-Laurent Casanova
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

Review 2.  The molecular basis of chronic granulomatous disease.

Authors:  C Meischl; D Roos
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.

Authors:  N Naumann; S S De Ravin; U Choi; M Moayeri; N Whiting-Theobald; G F Linton; Y Ikeda; H L Malech
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

4.  A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.

Authors:  Brandon K Wyss; Justin L Meyers; Anthony L Sinn; Shanbao Cai; Karen E Pollok; W Scott Goebel
Journal:  Exp Hematol       Date:  2008-02-04       Impact factor: 3.084

Review 5.  Genetics and immunopathology of chronic granulomatous disease.

Authors:  Marie José Stasia; Xing Jun Li
Journal:  Semin Immunopathol       Date:  2008-05-29       Impact factor: 11.759

6.  Cupric yersiniabactin is a virulence-associated superoxide dismutase mimic.

Authors:  Kaveri S Chaturvedi; Chia S Hung; Daryl E Giblin; Saki Urushidani; Anthony M Austin; Mary C Dinauer; Jeffrey P Henderson
Journal:  ACS Chem Biol       Date:  2013-12-11       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.